(Q34033665)

30 July 2017

0 references

Effectiveness of oseltamivir in adults: a meta-analysis of published and unpublished clinical trials (English)

1 reference

30 July 2017

0 references

1 reference

Mark H Ebell

1

1 reference

30 July 2017

Marlene Call

series ordinal

2

1 reference

30 July 2017

JoAnna Shinholser

series ordinal

3

1 reference

30 July 2017

language of work or name

English

0 references

publication date

20 September 2012

1 reference

30 July 2017

1 reference

30 July 2017

volume

30

1 reference

30 July 2017

issue

2

1 reference

30 July 2017

page(s)

125-133

1 reference

Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMS059

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMS059

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMS059

Antiviral and antibiotic prescribing for influenza in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMS059

Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMS059

Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMS059

Clinical efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir in treating acute influenza--placebo-controlled double-blind multicenter phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMS059

A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMS059

Uneasy alliance--clinical investigators and the pharmaceutical industry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMS059

Principles of appropriate antibiotic use for treatment of acute bronchitis in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMS059

Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMS059

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMS059

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMS059

Clinical benefits with oseltamivir in treating influenza in adult populations : results of a pooled and subgroup analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMS059

Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FFAMPRA%2FCMS059

21 January 2018

Identifiers

DOI

10.1093/FAMPRA/CMS059

1 reference

30 July 2017

1 reference